Mesalazine-induced eosinophilic pneumonia with bone marrow infiltration: a case report and literature review

Yunjian Zhang¹Ling Luo¹Xiaofang Wang¹Xiaoyang Liu¹Xiaoyan Wang¹Yi Ding²

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, ²Department of Pathology, Jishuitan Hospital, Fourth Medical College of Peking University, Beijing, People's Republic of China

Abstract: Mesalazine-induced eosinophilic pneumonia has been rarely reported. We reported a case of mesalazine-induced eosinophilic pneumonia in a 56-year-old female who took mesalazine without a prescription for suspected ulcerative colitis. She had an elevated eosinophil count in peripheral blood and bronchoalveolar lavage fluid. Eosinophil infiltration was also noted in bone marrow aspirates. Chest radiograph and computed tomography demonstrated bilateral upper lung predominant infiltrates and spirometry showed a restrictive ventilatory defect with a reduced diffusion capacity. The patient recovered after cessation of mesalazine therapy. Mesalazine-induced lung damage should be considered in patients who develop unexplained respiratory symptoms while taking this agent.

Keywords: mesalazine, pneumonia, eosinophil, colitis

Introduction

Mesalazine and other 5-aminosalicylate agents remain the current standard of care for inducing remission in mild-to-moderate active ulcerative colitis. Pulmonary toxicity secondary to mesalazine is very rare due to its lack of sulfapyridine moiety. Eosinophilic pneumonia is characterized by an abnormal accumulation of eosinophils in the lung, but apart from secondary causes, such as infection and medication, its etiology remains unknown. Though scattered case reports of mesalazine-associated interstitial lung diseases, such as organizing pneumonia, bronchitis obliterans, and interstitial lymphocytic pneumonia, are available,^{1–6} mesalazine-associated eosinophilic pneumonia has been sparsely reported.^{7–10} We report a case of eosinophilic pneumonia in a woman who took mesalazine for suspected ulcerative colitis and also carry out a literature review of reported cases of mesalazine-eosinophilic pneumonia.

Case report

This study was approved by the review boards of Jishuitan Hospital and Fourth Medical College of Peking University. Patient consent to this study was not required because the retrospective nature of the study. A 56-year-old woman was admitted to our hospital on July 1, 2015 because of intermittent fever and nonproductive cough for 2 weeks and exertional dyspnea and chest pain for 1 week. She described no chills, rigors, and night sweats. The patient developed abdominal pain and had mucus stools on April 20, 2015. Laboratory tests at a local clinic on May 20, 2015 showed leukocytes at $6.9 \times 10^9/L$ with 67.9% neutrophils and 0.12% eosinophils. Her hemoglobin level was 129 g/L and platelet count was $276 \times 10^9/L$. The occult stool test was weakly positive. She started

Correspondence: Yunjian Zhang
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Jishuitan Hospital, Fourth Medical College of Peking University, No 31, East Xijiekou Street, Xicheng District, Beijing 100035, People's Republic of China
Tel +86 136 9320 5037
Email zhangyjian@126.com

mesalazine 0.5 g three times a day for 6 weeks without a prescription. The patient began coughing on June 17, 2015 and also had fatigue and fever (as high as 39.4°C). Laboratory examinations revealed leukocytes at $12.75 \times 10^9/\text{L}$ with 76.2% neutrophils and 6.9% eosinophils. Her hemoglobin level stood at 124 g/L and platelet count was $485 \times 10^9/\text{L}$. A chest radiograph and computed tomography (CT) scan showed minor peripheral patchy opacity in bilateral upper and mid lungs with a narrowed right costophrenic angle (Figure 1A and B). A 10-day course of intravenous levofloxacin and ceftazidime was administered, and the patient continued mesalazine. Nevertheless, the patient was still febrile. On June 24, 2015, the patient developed right chest pain and aggravating exertional dyspnea. She denied symptoms of palpitations and paroxysmal nocturnal dyspnea. She denied the use of tobacco

products and had no occupational exposure to chemical fumes, including biomass fuel. The patient was allergic to penicillin and metronidazole. She had hypertension for 5 years, which was controlled by taking sustained release nifedipine. There was no family history of asthma.

Physical examination at admission showed a blood pressure of 117/70 mmHg, a pulse rate of 101 beats/min, a respiratory rate of 20 breaths/min, and a temperature of 37.4°C. No crackles were noted in both lungs. Clubbing, cyanosis, or peripheral edema was absent. Cardiovascular and abdominal examinations were unremarkable. Review of the systems was unremarkable for skin rashes, joint pain, and weight loss.

Laboratory investigations revealed leukocytes at $25.54 \times 10^9/\text{L}$ with 67.4% neutrophils and 21.8% eosinophils. Her hemoglobin was 111 g/L and platelet count $593 \times 10^9/\text{L}$.

Figure 1 Radiologic features of eosinophilic pneumonia in a 56-year-old woman who took mesalazine for suspected ulcerative colitis.

Notes: (A) Chest radiograph before admission (June 17, 2015) shows bilateral minor opacity in the upper lung fields, and (B) chest CT scan (June 27, 2015) reveals peripheral opacity in both lungs; (C) chest radiograph after admission (July 4, 2015) shows deterioration of bilateral opacity and (D) bilateral patchy consolidations with interlobular septal thickening in both lungs on CT scan (July 15, 2015). (E) CT scan upon discharge (August 6, 2015) shows bilateral minor ground glass opacity.

Abbreviation: CT, computed tomography.

Renal and liver function were normal, and no splenomegaly was noted. Chest radiograph showed progressing opacity predominantly in bilateral upper lungs (Figure 1C). Chest CT scan revealed bilateral patchy consolidations with interlobular septal thickening (Figure 1D and 1E). The single-breath diffusing capacity of the lung for carbon monoxide (DLco) was 46% of the predicted values. Transbronchial biopsy revealed chronic inflammation and exudation of fibrin (Figure 2A), and bronchoalveolar lavage fluid (BALF) showed 1×10^6 cells/mL with 18% macrophages, 22% neutrophils, 33% eosinophils, and 27% lymphocytes (Figure 2B). Bone marrow aspirate showed infiltration by mature eosinophils (Figure 2C), but the ratio of promyelocytes to their precursors was normal, and the percentage of eosinophils was 18, with normal morphology. Arterial blood gas analysis revealed a pH of 7.523, a partial pressure of carbon dioxide ($p\text{CO}_2$) of 29.7 mmHg, a partial pressure of oxygen ($p\text{O}_2$) of 59.5 mmHg, and a bicarbonate level of 23.2 mmol/L on room air. Tests for adenovirus, respiratory syncytial virus, seasonal influenza A and B,

parainfluenza virus, *Mycoplasma pneumoniae*, Chlamydia, and *Legionella pneumophila* were negative. Tuberculin skin test and sputum and BALF tests for acid-fast bacilli excluded tuberculosis. Rheumatoid factor, antinuclear antibodies, anti-double-strand DNA antibody, antiextractable nuclear antigen antibodies, and antineutrophil cytoplasmic antibody were negative. C-reactive protein was at 191 mg/dL, erythrocyte sedimentation rate was at 65 mm/h, and immunoglobulin E was at >100 IU/mL. Colonoscopy at 2 weeks after admission demonstrated focal erythema, erosions, and edematous swollen mucosa in the rectum.

Mesalazine-induced eosinophilic pneumonia was diagnosed, and mesalazine was discontinued. Currently, there is no consensus for the use of corticosteroid therapy for mesalazine-induced eosinophilic pneumonia, and our patient was not given corticosteroids. Besides, four out of nine reported cases also recovered without corticosteroid therapy. The patient improved in symptoms, and 4 weeks after cessation of mesalazine, she was discharged. CT scan showed bilateral ground glass opacity (Figure 1E). At 5 weeks of

Figure 2 Pathological findings.

Notes: (A) Transbronchial biopsy reveals chronic inflammation and exudation of fibrin. (B) Photomicrograph of BALF shows infiltration by eosinophils (arrow), hematoxylin and eosin stain $\times 400$. (C) Photomicrograph of bone marrow aspirate shows infiltration by mature eosinophils (arrow), Wright–Giemsa stain $\times 1,000$.

Abbreviation: BALF, bronchoalveolar lavage fluid.

Figure 3 Changes in eosinophil counts.

Note: Arrow indicates date of mesalazine cessation.

Abbreviation: EOS, eosinophils.

follow-up after discharge, the patient was asymptomatic with a normalized eosinophil count (Figure 3). Spirometry continued to show a restrictive defect and a reduced DLco (44%) (Table 1), but the patient felt no apparent exertional dyspnea after discharge.

Discussion

Eosinophilic pneumonia is characterized by eosinophilic infiltration in the lungs, radiographic abnormalities, impaired lung function, and peripheral blood eosinophilia. The causes of eosinophilic pneumonia remain largely unknown, and the disease may occur secondary to medications, such as mesalazine. We describe a case of eosinophilic pneumonia in a woman who took mesalazine for proctitis. The case was confirmed by clinical manifestations, medication history, BALF cytology, and radiological findings. The case is noted for eosinophilia in peripheral blood and for infiltration of mature eosinophils in the lungs and the bone marrow. Though it has not been reported in mesalazine-associated eosinophilic pneumonia, eosinophil infiltration

in the bone marrow due to other drugs, such as minocycline, has been described.¹¹

The first case of mesalazine-induced lung hypersensitivity was reported in 1991.¹² Over the past two decades, several cases of mesalazine-induced pulmonary toxicity have been reported, particularly eosinophilic pneumonia.^{7,9,13–19} The incidence of lung disease from mesalazine is unknown; however, reports from mesalazine-induced lung disease have increased, and the pathogenesis is still unknown.⁸ Immune-mediated injury and direct cytotoxic effect are considered as causes of drug-induced lung injury.

Symptoms related to mesalazine-induced eosinophilic pneumonia can range from being asymptomatic to fever, cough, and shortness of breath. Women were reported to be affected more often than men.⁶ Among nine previously published case reports of mesalazine-induced eosinophilic pneumonia, there were three males^{13,16,17} and six females^{7,9,14,15,18,19} with a mean age of 34 years (ranging from 23 years to 50 years). Most cases occurred between 1 month and 7 months after the initiation of the drug, with rare cases occurring 2 years later.^{7,9,13–19} The clinicopathologic and radiologic features of these patients and our patient are summarized in Table 2.

The diagnosis of mesalazine-induced eosinophilic pneumonia can be challenging. Laboratory tests may reveal peripheral eosinophilia. Eosinophilia in peripheral blood was found in all nine patients previously reported with eosinophils ranging from 16% to 63%.^{7,9,13–19} Arterial blood gas can show hypoxia. Pulmonary function tests usually demonstrate a restrictive picture with a reduced diffusing capacity as seen in our case. Nonspecific interstitial infiltrate or consolidation is usually seen in the chest radiograph or CT scan. In some cases, characteristic finding described as wandering shadow is observed.^{7,16} If the diagnosis remains unclear, bronchoscopy and BAL should be performed. The BAL frequently shows an elevated count of eosinophils, while transbronchial lung biopsy may reveal interstitial infiltrates or alveolar exudates. Preferably, the presence of eosinophilia in peripheral blood, BAL, or lung tissue should be used as indicators for diagnosing mesalazine-induced eosinophilic pneumonia in patients with a medication history of mesalazine.

Table 1 Changes in respiratory function in the patient

	FVC (L, %pred)	FEV ₁ (L, %pred)	FEV ₁ / FVC (%)	TLC (L, %pred)	RV (L, %pred)	RV/ TLC (%)	DLco (%pred)
July 28, 2015	1.83 (72%)	1.54 (73%)	84	1.84 (47%)	0.71 (50%)	39	46
August 6, 2015	2.18 (86%)	1.69 (80%)	77	3.73 (95%)	1.54 (110%)	41	56
September 9, 2015	2.55 (93%)	2.04 (91%)	80	3.33 (77%)	0.78 (50%)	23	44

Abbreviations: FVC, forced vital capacity; FEV₁, forced expiratory volume in one second; TLC, total lung capacity; RV, residual volume; DLco, diffusing capacity of the lung for carbon monoxide.

Table 2 Clinicopathologic, radiologic, and treatment outcomes of reported cases of mesalazine-associated eosinophilic pneumonia

Authors (country)	Age/ sex	Primary disease	Onset time	Clinical manifestations	Imaging features	Pathology	EOS% in BALF	EOS% in peripheral blood	Intervention	Prognosis
Ferrusquía et al ¹³ (Spain)	32/M	UC	12 months	Fever, fatigue, night sweats, dyspnea, dry cough, and chest pain	Left lower lobe and lingual lobe nodules, mediastinal lymphadenopathy, bilateral lower lung ground glass opacity 4 weeks later, and pericardial effusion	TBLB, bulla, and vascular and interstitial eosinophil infiltration	72	63	Cessation + steroid hormone	Peripheral eosinophil count is normal several days after mesalazine cessation, and imaging abnormalities disappear. DLco is still low at 6 months
Kim et al ⁹ (South Korea)	30/F	UC	19 days	Fatigue, muscle ache, and coughing	Bilateral peripheral consolidations and thickened septa	Biopsy reveals bulla, giant macrophages, and eosinophils	1.6	24.5	Cessation + steroid hormone	Full recovery
Fayaz et al ¹⁴ (UK)	24/F	UC	2 years	Dyspnea and chest pain	Bilateral infiltrates and left pleural effusion	Thoracoscope reveals eosinophilic granuloma	NA	Elevated	Cessation	Full recovery
Shimizu et al ¹⁵ (Japan)	50/F	UC	1 month	Fever and dry cough	Bilateral infiltrates	NA	20	NA	Cessation	Full recovery
Park et al ¹⁶ (South Korea)	35/M	CD	Unknown	Fever and dry cough	Bilateral migratory infiltrates	NA	Elevated	Elevated	Cessation	Full recovery
Hakoda et al ¹⁷ (Japan)	30/M	UC	1 month	Fever and coughing	Bilateral infiltrates	TBLB and unknown	Elevated	Elevated	Cessation + steroid hormone	Recovery
Zamir et al ¹⁸ (Israel)	23/F	UC	2 months	Fever and coughing	Bilateral peripheral infiltrates	NA	NA	Elevated	Cessation + steroid hormone	Symptoms and imaging abnormalities disappear at one week
Tanigawa et al ⁷ (Japan)	35/F	UC	6 months	Low fever and dry cough	Bilateral migratory infiltrates	TBLB and organizing eosinophilic pneumonia	NA	NA	Cessation	Recovery
Honeybourne ¹⁹ (UK)	30/F	UC	7 months	Intermittent fever, body weight loss, dry cough, progressive dyspnea, and chest pain	Bilateral apex predominant infiltrates and mild bilateral pleural effusion	Thoracoscopic biopsy reveals chronic eosinophilic pneumonia	NA	16	Cessation	Normal imaging and eosinophil count several weeks later
The current case	56/F	Proctitis	1 month	Fever, fatigue, dry cough, and dyspnea	Bilateral upper lung predominant infiltrates	TBLB and bulla and massive eosinophils	33	21.8	Cessation	Improvement at 1 week, normal imaging at 4 weeks, and normal eosinophil count at 2 months

Abbreviations: EOS, eosinophils; BALF, bronchoalveolar lavage fluid; UC, ulcerative colitis; TBLB, transbronchial lung biopsy; DLco, diffusing capacity of the lung for carbon monoxide; NA, not available or not done; CD, Crohn's disease; F, female; M, male.

The most essential aspect of diagnosing mesalazine-induced eosinophilic pneumonia is a high index of suspicion. A detailed history and laboratory and diagnostic studies can help to distinguish inflammatory bowel disease-associated lung involvement from mesalazine-related toxicity. In the present patient, it is reasonable to establish a diagnosis of mesalazine-induced pneumonia for several reasons: 1) the appearance of respiratory symptoms during drug therapy; 2) clinical, radiological, and BALF findings consistent with mesalazine-induced eosinophilic lung disease; 3) the absence of established criteria required for diagnosing inflammatory bowel disease; 4) other lung diseases, such as those due to infections, were excluded; 5) clinical and radiological improvements after mesalazine discontinuation.

The most important aspect of treatment involves discontinuation of therapy with mesalazine. Mesalazine cessation usually leads to improvement in both clinical and radiographic pictures. The role of steroids for mesalazine-induced eosinophilic pneumonia is unclear. Corticosteroid therapy can lead to rapid recovery. However, several reports also describe full recovery after discontinuation of mesalazine without steroid therapy.^{7,15,16,19} Our patient also markedly improved by simple cessation of mesalazine intake. The prognosis of mesalazine-induced lung injury is good.

One limitation of this report is that transbronchial biopsy failed to detect infiltration by eosinophils in the lung tissues of the patient. This is probably due to the small area of lung tissues that can be biopsied via the transbronchial approach. The biopsy site may not be representative of lesions characteristic of eosinophilic pneumonia. It remains to be seen whether increasing the number of biopsies at multiple sites would lead to a higher rate of positive finding.

Conclusion

Mesalazine-induced eosinophilic pneumonia is an extremely rare entity. Clinical and imaging manifestations are not specific. The diagnosis is relied on the history of mesalazine therapy, eosinophilia in blood, pulmonary histiocytic infiltration with eosinophils, and marked improvement of symptoms and radiologic abnormalities after the discontinuation of mesalazine. The possibility of drug-induced eosinophilic pneumonia should be fully considered in patients developing unexplained respiratory symptoms while on mesalazine therapy.

Acknowledgment

This work was supported by the Project of Beijing Municipal Science and Technology Commission (Z141107002514153).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Michy B, Raymond S, Graffin B. Pneumopathie organisée apparue sous mésalazine [Organizing pneumonia during treatment with mesalazine]. *Rev Mal Respir*. 2014;31(1):70–77.
2. Shindoh Y, Horaguchi R, Hayashi K, Suda Y, Iijima H, Shindoh C. [A case of lung injury induced by long-term administration of mesalazine]. *Nihon Kokyuki Gakkai Zasshi/Jpn Respir Soc*. 2011; 49(11):861–866. Japanese.
3. Đurić M, Považan Đ, Sečen S, Jović J. Differential diagnosis problem of pulmonary changes in ulcerative colitis. *Vojnosanit Pregl*. 2010;67(6): 511–514.
4. Taguchi S, Furuta J, Ohara G, Kagohashi K, Satoh H. Severe airflow obstruction in a patient with ulcerative colitis and toxic epidermal necrolysis: a case report. *Exp Ther Med*. 2015;9(5):1944–1946.
5. Haralambou G, Teirstein AS, Gil J, Present DH. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. *Mt Sinai J Med*. 2001;68(6):384–388.
6. Sossai P, Cappellato MG, Stefani S. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine. *Mt Sinai J Med*. 2001;68(6):389–395.
7. Tanigawa K, Sugiyama K, Matsuyama H, et al. Mesalazine-induced eosinophilic pneumonia. *Respiration*. 1999;66(1):69–72.
8. Inoue M, Horita N, Kimura N, Kojima R, Miyazawa N. Three cases of mesalazine-induced pneumonitis with eosinophilia. *Respir Investig*. 2014;52(3):209–212.
9. Kim JH, Lee JH, Koh ES, et al. Acute eosinophilic pneumonia related to a mesalazine suppository. *Asia Pac Allergy*. 2013;3(2):136–139.
10. Franco AI, Escobar L, Garcia XA, et al. Mesalazine-induced eosinophilic pneumonia in a patient with ulcerative colitis disease: a case report and literature review. *Int J Colorectal Dis*. 2016;31(4):927–929.
11. Bentur L, Bar-Kana Y, Livni E, et al. Severe minocycline-induced eosinophilic pneumonia: extrapulmonary manifestations and the use of in vitro immunoassays. *Ann Pharmacother*. 1997;31(6):733–735.
12. Le Gros V, Saveuse H, Lesur G, Brion N. Lung and skin hypersensitivity to 5-aminosalicylic acid. *Br Med J*. 1991;302(6782):970.
13. Ferrusquía J, Pérez-Martínez I, Gómez de la Torre R, et al. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. *World J Gastroenterol*. 2015;21(13):4069–4077.
14. Fayaz M, Sultan A, Nawaz M, Sultan N. Mesalazine-induced eosinophilic variant of Wegener's granulomatosis in an ulcerative colitis patient. *J Ayub Med Coll Abbottabad*. 2009;21(4):171–173.
15. Shimizu T, Hayashi M, Shimizu N, Kinebuchi S, Toyama J. [A case of mesalazine-induced lung injury improved by only discontinuation of mesalazine]. *Nihon Kokyuki Gakkai Zasshi/Jpn Respir Soc*. 2009; 47(6):543–547. Japanese.
16. Park JE, Hwangbo Y, Chang R, et al. [Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease]. *Korean J Gastroenterol/Taehan Sohwagi Hakhoe chi*. 2009;53(2):116–120. Korean.
17. Hakoda Y, Aoshima M, Kinoshita M, Sakurai M, Ohyashiki K. [A case of eosinophilic pneumonia possibly associated with 5-aminosalicylic acid (5-ASA)]. *Nihon Kokyuki Gakkai Zasshi/Jpn Respir Soc*. 2004; 42(5):404–409. Japanese.
18. Zamir D, Weizman J, Zamir C, Fireman Z, Weiner P. [Mesalamine-induced hypersensitivity pneumonitis]. *Harefuah*. 1999;137(1–2): 28–30, 87, 86. Hebrew.
19. Honeybourne D. Mesalazine toxicity. *Br Med J*. 1994;308(6927):533.

Therapeutics and Clinical Risk Management

Dovepress

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS,

EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>